Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$3.65 -0.3%	$3.20	$2.01 ▼ $5.64	$243.49M	1.52	1.20 million shs	993,961 shs
EPRX Eupraxia Pharmaceuticals	$5.54 +2.8%	$4.21	$2.20 ▼ $6.20	$193.81M	1.55	13,277 shs	6,820 shs
INMB INmune Bio	$2.30 -9.1%	$6.76	$1.89 ▼ $11.64	$59.67M	1.34	787,829 shs	3.28 million shs
MDWD MediWound	$19.27 -0.4%	$19.76	$14.14 ▼ $22.51	$209.03M	0.32	71,229 shs	46,507 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	-0.16%	+15.87%	-5.93%	+43.14%	+65.16%
EPRX Eupraxia Pharmaceuticals	+1.35%	-3.84%	+40.76%	+86.50%	+120.24%
INMB INmune Bio	-11.71%	-0.43%	-69.82%	-66.37%	-70.63%
MDWD MediWound	-1.03%	-0.52%	-10.79%	+25.54%	-1.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	1.669 of 5 stars	3.4	1.0	2.7	0.0	0.6
EPRX Eupraxia Pharmaceuticals	2.4506 of 5 stars	3.6	1.0	2.9	0.0	0.6
INMB INmune Bio	1.5753 of 5 stars	3.3	0.0	2.0	1.7	0.6
MDWD MediWound	1.6108 of 5 stars	3.5	1.0	1.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.80	Moderate Buy	$9.88	170.55% Upside
EPRX Eupraxia Pharmaceuticals	3.20	Buy	$11.00	98.59% Upside
INMB INmune Bio	2.57	Moderate Buy	$18.40	700.00% Upside
MDWD MediWound	3.00	Buy	$31.80	65.02% Upside

Current Analyst Ratings Breakdown

Latest INMB, CRDF, MDWD, and EPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/16/2025	EPRX Eupraxia Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Speculative Buy
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	357.11	N/A	N/A	$1.86 per share	1.96
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	$10K	5,423.40	N/A	N/A	$1.45 per share	1.59
MDWD MediWound	$19.21M	10.84	N/A	N/A	$2.89 per share	6.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$25.50M	-$0.76	N/A	N/A	N/A	N/A	-367.73%	-112.23%	8/6/2025 (Estimated)
INMB INmune Bio	-$42.08M	-$1.93	N/A	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)
MDWD MediWound	-$30.22M	-$2.09	N/A	N/A	N/A	-110.45%	-74.12%	-30.92%	8/13/2025 (Estimated)

Latest INMB, CRDF, MDWD, and EPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	6.22	6.22
EPRX Eupraxia Pharmaceuticals	N/A	11.10	11.10
INMB INmune Bio	N/A	2.64	2.64
MDWD MediWound	N/A	2.15	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
EPRX Eupraxia Pharmaceuticals	N/A
INMB INmune Bio	12.72%
MDWD MediWound	46.83%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
EPRX Eupraxia Pharmaceuticals	N/A
INMB INmune Bio	35.70%
MDWD MediWound	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
INMB INmune Bio	10	23.58 million	15.17 million	Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable

INMB, CRDF, MDWD, and EPRX Headlines

Recent News About These Companies

MediWound Ltd. (NASDAQ:MDWD) is definitely on the radar of institutional investors who own 42% of the company

July 7 at 9:02 AM | finance.yahoo.com

MediWound Ltd. (NASDAQ:MDWD) Receives Consensus Rating of "Buy" from Analysts

July 2, 2025 | americanbankingnews.com

MediWound Ltd. (NASDAQ:MDWD) Given Average Rating of "Buy" by Analysts

June 27, 2025 | marketbeat.com

MediWound Ltd. (MDWD) latest stock news and headlines - Yahoo Finance

June 26, 2025 | sg.finance.yahoo.com

MediWound (NASDAQ:MDWD) Shares Pass Above Fifty Day Moving Average - Time to Sell?

June 25, 2025 | marketbeat.com

Companies Like MediWound (NASDAQ:MDWD) Are In A Position To Invest In Growth

June 2, 2025 | finance.yahoo.com

MediWound’s Q1 2025: Strategic Progress Amid Financial Challenges

May 21, 2025 | tipranks.com

MediWound (MDWD) Q1 2025 Earnings Call Transcript

May 21, 2025 | msn.com

MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript

May 21, 2025 | seekingalpha.com

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

May 21, 2025 | zacks.com

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 21, 2025 | globenewswire.com

MediWound Q1 2025 Earnings Preview

May 20, 2025 | msn.com

MediWound Ltd.: Undervalued High-Growth Potential

May 16, 2025 | seekingalpha.com

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

May 13, 2025 | globenewswire.com

MediWound to Report First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

April 28, 2025 | globenewswire.com

Those who invested in MediWound (NASDAQ:MDWD) five years ago are up 30%

April 17, 2025 | finance.yahoo.com

MediWound reports Q4 EPS (36c), consensus (61c)

March 20, 2025 | markets.businessinsider.com

MediWound files $125M mixed securities shelf

March 20, 2025 | markets.businessinsider.com

Loss-Making MediWound Ltd. (NASDAQ:MDWD) Expected To Breakeven In The Medium-Term

March 20, 2025 | finance.yahoo.com

MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript

March 20, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB, CRDF, MDWD, and EPRX Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$3.65 -0.01 (-0.27%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$3.74 +0.10 (+2.60%)

As of 07:09 AM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.54 +0.15 (+2.76%)

Closing price 07/7/2025 03:04 PM Eastern

Extended Trading

$5.70 +0.16 (+2.91%)

As of 07:11 AM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

INmune Bio NASDAQ:INMB

$2.30 -0.23 (-9.09%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$2.32 +0.02 (+0.65%)

As of 07:31 AM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

MediWound NASDAQ:MDWD

$19.27 -0.07 (-0.36%)

As of 07/7/2025 04:00 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time